Zentalis Pharmaceuticals Inc
For the period ended Jun 30, 2024. Filed Aug 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 9, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information.
Personnel Update
Effective August 8, 2024, Diana Hausman, M.D., has stepped down and is no longer serving as the Company’s Chief Medical Officer. The Company is conducting a search for a new Chief Medical Officer. The Company’s Chief Executive Officer, Kimberly Blackwell, M.D., will serve as the Company’s Interim Chief Medical Officer.
The foregoing information is included for the purpose of providing the disclosures required under “Item 8.01 – Other Events” of Form 8-K.
Insider Trading Arrangements and Policies.
On May 2, 2024, a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c), originally adopted on December 5, 2023 by Diana Hausman, M.D., the Company’s former Chief Medical Officer, for the sale of up to 13,244 shares of the Company’s common stock until May 31, 2025, wasterminated.
On June 17, 2024, a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c), originally adopted on November 16, 2023 by Jan Skvarka, a member of the Company’s Board of Directors, for the sale of up to 11,368 shares of the Company’s common stock until December 31, 2024, wasterminated.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.